ABRYSVO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Lithuania, Romania, Spain.

Active ingredients

The drug ABRYSVO contains one active pharmaceutical ingredient (API):

1	RSV glycoprotein F antigen
	RSV glycoprotein F antigen is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01E facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells.
	Read more about RSV glycoprotein F antigen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ABRYSVO Powder and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BX05		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3044618, 3044629, 3044630
ES	Centro de información online de medicamentos de la AEMPS	1231752001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	587002
FR	Base de données publique des médicaments	60990140
IT	Agenzia del Farmaco	050831015, 050831027, 050831039, 050831041, 050831054, 050831066
LT	Valstybinė vaistų kontrolės tarnyba	1097701, 1097702, 1097703, 1097704, 1097705, 1097706
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69758001, W69758002, W69758003, W69758004, W69758005, W69758006
US	FDA, National Drug Code	0069-0207, 0069-0250, 0069-0344